[Back to Issue 7 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]
[View Full Article] [Download Reprint (PDF)]

Localization of Mullerian Inhibiting Substance Receptors in Various Human Cancer Cell Lines

A. V. Rodina*, N. V. Gukasova, V. A. Makarov, I. G. Kondrasheva, A. V. Khomyakova, G. A. Posypanova, O. N. Popova, E. Yu. Moskaleva, and S. E. Severin

Moscow Research Institute of Medical Ecology, Moscow Department of Health Care, Simferopolsky blvd. 8, 117638 Moscow, Russia; fax: (499) 613-4818; E-mail: sergsev@aha.ru; allrodina@yandex.ru

* To whom correspondence should be addressed.

Received January 15, 2008; Revision received March 7, 2008
Recombinant human MIS (rhMIS) produced in transfected Chinese hamster ovary cells has been purified by immunoaffinity chromatography. In the absence of reducing agents, 140 kD homodimer and several oligomers with molecular masses from 280 to 1000 kD are present. Homodimer, tetramer, and higher-molecular-weight rhMIS fractions reduced survival of tumor cells. For these experiments, FITC-labeled rhMIS was used for binding and endocytosis studies by flow cytometry. Flow cytometry performed on MIS-sensitive cancer cell lines demonstrated specific binding of rhMIS. The majority of rhMIS receptors have cytosolic localization. Thus, the level of MIS receptors on the cell membrane was proportional to the content of MIS-binding proteins in the whole cell and defines a level of receptor-mediated endocytosis. The immunopurified rhMIS caused significant growth inhibition of ovarian and prostate adenocarcinoma and melanoma human cell lines in inhibition assays.
KEY WORDS: human recombinant MIS, receptor localization, biological activity

DOI: 10.1134/S0006297908070080